Program
bizalimogene ralaplasmid
Also written as “VGX-3100” and “VGX 3100”.
Its studies are mostly in Uterine Cervical Dysplasia · Squamous Intraepithelial Lesions · Anus Neoplasms · Uterine Cervical Neoplasms · Papillomavirus Infections, led by Inovio Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Inovio Pharmaceuticals | 70 open or running | phase 3since Jun 9, 2017 | May 22, 2008 | none ahead |
- Named in fosun pharma’s own pipeline as
VGX-3100
, phase 3, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2008First study: phase 1 study in Papillomavirus InfectionsFirst studyNCT00685412 · 18 enrolled · United States, Puerto Rico
- Aug 5, 2010Phase 1 study in Uterine Cervical NeoplasmsNCT01188850 · 14 enrolled · United States, Puerto Rico
- Feb 16, 2011Phase 2 study in Uterine Cervical DysplasiaNCT01304524 · 167 enrolled · United States, Australia, Canada and more
- Jun 6, 2017Phase 2 study in Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)NCT03180684 · 33 enrolled · United States
- Jun 9, 2017Phase 3 study in Uterine Cervical DysplasiaNCT03185013 · 201 enrolled · United States, Argentina, Belgium and more
- Apr 9, 2018Phase 2 study in Anus NeoplasmsNCT03499795 · 23 enrolled · United States, Canada
- Oct 25, 2018Phase 3 study in Uterine Cervical DysplasiaNCT03721978 · 203 enrolled · United States, Argentina, Brazil and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03721978Uterine Cervical Dysplasia · United States, Argentina, Brazil and more | 3 | Completed | Aug 23, 2022 | 203 |
| NCT03499795Anus Neoplasms · United States, Canada | 2 | Completed | Jun 16, 2020 | 23 |
| NCT03185013Uterine Cervical Dysplasia · United States, Argentina, Belgium and more | 3 | Completed | Jul 8, 2020 | 201 |
| NCT03180684Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · United States | 2 | Completed | Jul 23, 2020 | 33 |
| NCT01304524Uterine Cervical Dysplasia · United States, Australia, Canada and more | 2 | Completed | May 2014 | 167 |
| NCT01188850Uterine Cervical Neoplasms · United States, Puerto Rico | 1 | Completed | Oct 2011 | 14 |
| NCT00685412Papillomavirus Infections · United States, Puerto Rico | 1 | Completed | Jan 2011 | 18 |
How it is read
Names in the registry
- “VGX-3100”, 6 entries
- “VGX 3100”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Dysplasia, 3 studies
- Squamous Intraepithelial Lesions, 1 study
- Anus Neoplasms, 1 study
- Uterine Cervical Neoplasms, 1 study
- Papillomavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.